Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
United European Gastroenterology Journal · 2025
DOI: 10.1002/ueg2.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Jonas Buchloh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany. Hauptthemen laut MEDLINE: Rectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
Emerging RAS inhibitors show promise in treating KRAS‐mutated malignancies, but resistance mechanisms limit their clinical efficacy. Given recent clinical findings associating KRAS mutations with reduced response to neoadjuvant therapy in rectal cancer (RC), we aimed to investigate their impact on treatment outcomes and explore potential therapeutic strategies.
Methods
We conducted a retrospective analysis of 390 rectal cancer patients to evaluate the association of KRAS mutations with disease‐free survival (DFS) and response to therapy. We assessed the efficacy of KRAS inhibitors in rectal cancer cell lines, patient‐derived organoids (PDOs), and patient‐derived cell lines (PDCLs), and explored adaptive resistance mechanisms through transcriptomic profiling and unbiased drug screening experiments.
Results
Mutant KRAS was associated with a reduced DFS and RCs harboring G12C and G12V mutations had less complete pathological responses to neo‐adjuvant therapies. KRAS‐mutated RC cells demonstrated adaptive resistance to KRAS inhibitors, characterized by transcriptomic restoration of oncogenic pathways, including MYC and E2F, and upregulation of ERBB2/3 expression. Consistently, drug screening identified EGFR family inhibitors as potent combinatorial partners, effectively overcoming KRAS inhibitor tolerance by inducing apoptosis. In patient‐derived models, the pan‐RAS inhibitor RMC‐6236 combined with EGFR inhibitors demonstrated significant synergistic effects and prevented long‐term tumor cell outgrowth.
Conclusion
Our findings point to the negative impact of KRAS mutations, particularly G12C and G12V, on RC treatment outcomes. Adaptive resistance by upregulation of ERBB genes limits the efficacy of KRAS inhibitors. Combining these with pan‐ERBB inhibitors enhances anti‐tumor effects in patient‐derived cellular RC models, showing its potential as an alternative to the combination with anti‐EGFR antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
- Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
- Molecular Oncology and Immunotherapy, Clinic of General Surgery, University Medical Center Rostock, Rostock, Germany.
- Clinic für General- and Visceral Surgery, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
- CCC-N (Comprehensive Cancer Center Lower Saxony), Göttingen, Germany.
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Xin Fang, Günter Schneider
Förderung
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Buchloh, J., Spitzner, M., Zimmermann, H., Fang, X., Tapia Contreras, C., Schneider, C., de Oliveria, T., Küffer, S., Linnebacher, M., Rühlmann, F., Conradi, L., Wirth, M., Ghadimi, M., Grade, M., Gaedcke, J., & Schneider, G. (2025). Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70086
Vancouver
Buchloh J, Spitzner M, Zimmermann H, Fang X, Tapia Contreras C, Schneider C, et al. Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.70086
BibTeX
@article{Buchloh2025,
author = {Buchloh, Jonas and Spitzner, Melanie and Zimmermann, Hauke and Fang, Xin and Tapia Contreras, Constanza and Schneider, Carolin and de Oliveria, Tiago and Küffer, Stefan and Linnebacher, Michael and Rühlmann, Felix and Conradi, Lena and Wirth, Matthias and Ghadimi, Michael and Grade, Marian and Gaedcke, Jochen and Schneider, Günter},
title = {Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer},
journal = {United European Gastroenterology Journal},
year = {2025},
doi = {10.1002/ueg2.70086}
}
EUVIMED